FDA approves BeiGene’s TEVIMBRA for esophageal cancer treatment
In a notable advancement in the oncology sector, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a globally recognized oncology company, has received approval from ... Read More
FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction in adults with obesity
The U.S. Food and Drug Administration (FDA) has recently granted an additional indication for Novo Nordisk's Wegovy, a milestone in medical advancements aimed at combating ... Read More
Bristol Myers Squibb announces Opdivo FDA approval for urothelial carcinoma
In a significant stride toward enhancing bladder cancer treatment, Bristol Myers Squibb (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) approval of Opdivo ... Read More
IM Cannabis and Kadimastem announce reverse merger deal
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), known for its significant strides in the medical cannabis sector, has announced a business combination with Kadimastem Ltd, ... Read More
FDA approves G1 Therapeutics’ Cosela for reducing chemotherapy-induced bone marrow suppression
G1 Therapeutics has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval of Cosela (trilaciclib), a pioneering treatment designed to ... Read More
Janssen Pharmaceutical’s DARZALEX FASPRO gains FDA approval for AL amyloidosis treatment
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), marking a major milestone in the treatment ... Read More
Biocon expands generics portfolio with Tacrolimus launch in US
Biocon, the prominent Indian biopharmaceutical company, has made a significant leap in the US pharmaceutical market with the launch of its generic Tacrolimus capsules. This ... Read More
AstraZeneca secures extended FDA approval for Tagrisso as adjuvant treatment in early-stage lung cancer
AstraZeneca has announced a significant breakthrough with the United States Food and Drug Administration (FDA) granting extended approval for its drug Tagrisso (osimertinib) as an ... Read More
Roche to strengthen gene therapy portfolio with Spark Therapeutics acquisition
Swiss pharmaceutical giant Roche has reached a major agreement to acquire the U.S.-based gene therapy company Spark Therapeutics in an all-cash deal valued at $4.3 ... Read More
Roche’s Tecentriq secures FDA approval for small cell lung cancer treatment
Roche’s subsidiary, Genentech, has announced a significant breakthrough with the US Food and Drug Administration (FDA) approval of Tecentriq (atezolizumab). This new approval marks a ... Read More